Use of cabergoline for the management of persistent Cushing's disease in pregnancy

BMJ Case Rep. 2017 Jul 14:2017:bcr2016217855. doi: 10.1136/bcr-2016-217855.

Abstract

Cushing's disease (CD) is rare during pregnancy and is associated with significant maternal and fetal complications. It is important to control hypercortisolism during pregnancy, either surgically or medically, for a successful maternal and fetal outcome. We report a patient with recurrent CD who was treated with low-dose cabergoline (CAB) for persistent hypercortisolism throughout pregnancy. A 36-year-old woman was diagnosed with CD at the age of 23. She underwent trans-sphenoidal surgery with initial complete remission. However, 4 years after surgery, CD recurred and she underwent Gamma Knife radiosurgery (GKRS). Following GKRS, her cortisol levels remained elevated despite no evidence of visible tumour on pituitary MRI. Medical treatment was commenced with ketoconazole and cyproheptadine. This was changed to CAB as she was keen for pregnancy. She conceived spontaneously and was on CAB throughout pregnancy. She delivered a healthy male neonate, weighing 3195 g at 40 weeks of gestation.

Keywords: endocrine system; pituitary disorders; pregnancy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Cabergoline
  • Diagnosis, Differential
  • Ergolines / administration & dosage
  • Ergolines / therapeutic use*
  • Female
  • Humans
  • Pituitary ACTH Hypersecretion / blood
  • Pituitary ACTH Hypersecretion / diagnosis*
  • Pituitary ACTH Hypersecretion / drug therapy
  • Pregnancy
  • Pregnancy Complications / blood
  • Pregnancy Complications / diagnosis*
  • Pregnancy Complications / drug therapy
  • Prenatal Diagnosis*
  • Recurrence
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Ergolines
  • Cabergoline